|
1）Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110: 673-87
|
|
|
|
2）Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol. 2010; 11: 288-300
|
|
|
|
|
|
3）Moser M, Legate KR, Zent R, et al. The tail of integrins, talin, and kindlins. Science. 2009; 324: 895-9
|
|
|
|
|
|
4）Tadokoro S, Shattil SJ, Eto K, et al. Talin binding to integrin β tails: a final common step in integrin activation. Science. 2003; 302: 103-6
|
|
|
|
|
|
5）Petrich BG, Marchese P, Ruggeri ZM, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med. 2007; 204: 3103-11
|
|
|
|
|
|
6）Nieswandt B, Moser M, Pleines I, et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med. 2007; 204: 3113-8
|
|
|
|
|
|
7）Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008; 14: 325-30
|
|
|
|
|
|
8）Moser M, Bauer M, Schmid S, et al. Kindlin-3 is required for β2 integrin-mediated leukocyte adhesion to endothelial cells. Nat Med. 2009; 15: 300-5
|
|
|
|
|
|
9）Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med. 2009; 15: 306-12
|
|
|
|
|
|
10）Lefort CT, Rossaint J, Moser M, et al. Distinct roles for talin-1 and kindlin-3 in LFA-1 extension and affinity regulation. Blood. 2012; 119: 4275-82
|
|
|
|
|
|
11）Tadokoro S, Nakazawa T, Kamae T, et al. A potential role for α-actinin in inside-out αIIbβ3 signaling. Blood. 2011; 117: 250-8
|
|
|
|
|
|
12）Rantala JK, Pouwels J, Pellinen T, et al. SHARPIN is an endogenous inhibitor of β1-integrin activation. Nat Cell Biol. 2011; 13: 1315-24
|
|
|
|
|
|
13）Kim C, Schmidt T, Cho EG, et al. Basic amino-acid side chains regulate transmembrane integrin signalling. Nature. 2011; 481: 209-13
|
|
|
|
|
|
14）Naik MU, Stalker TJ, Brass LF, et al. JAM-A protects from thrombosis by suppressing integrin αIIbβ3-dependent outside-in signaling in platelets. Blood. 2012; 119: 3352-60
|
|
|
|
|
|
15）Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci. 2012; 33: 405-12
|
|
|
|
|